Skip to content
value.today

Elite Pharmaceuticals, Inc.

ELTP
$42 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$149 M
For year ending March-2026
Net income
$45 M
30.1% margin
SEC filing
Employees
65
As of June 25, 2026
SEC filing

Elite Pharmaceuticals, Inc. in brief

Elite Pharmaceuticals, Inc. is a listed company in the Pharmaceutical industry, based in Northvale, New Jersey, USA. Its last known market value was $42 M (January 2022); there is no current figure. In the year to March 2026 it had sales of $149 M and a net profit of $45 M, about 30 cents of profit for every dollar of sales. It employs about 65 people. Its largest product and service lines by sales in 2026 were Manufacturing (99%), Manufacturing Fees (99%) and Scheduled Products Manufacturing Fees (95%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc., a Nevada corporation was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc., was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.

We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry.

From the company's annual report filed with the US SEC: read the report

Elite Pharmaceuticals, Inc. timeline

4 events, 1998–2025
  1. 1998
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2012
  4. ✎
    Renamed Elite Pharmaceuticals Inc /Nv/
    Formerly Elite Pharmaceuticals Inc /De/.
  5. 2025
  6. 💰
    Record revenue of $149 million
    FY2025, the highest of the 8 years on record.
  7. 💰
    Record net income of $45 million
    FY2025, the highest profit of the 5 years on record.

Events of Elite Pharmaceuticals, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
41.6%
Operating margin
33.0%
Return on equity
61.0%
Liabilities / assets
28.5%
Net debt
$-7M
Revenue growth
+77.1%
R&D / revenue
3.9%
Revenue per employee
$2.3 M
Profit per employee
$690 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue $8M, net income $-9M$8MFY19Fiscal year ending Mar 2020: revenue $18M, net income $-2M$18MFY20Fiscal year ending Mar 2021: revenue $25M, net income $5M$25MFY21Fiscal year ending Mar 2022: revenue $32M, net income $9M$32MFY22Fiscal year ending Mar 2023: revenue $34M, net income $4M$34MFY23Fiscal year ending Mar 2024: revenue $57M, net income $20M$57MFY24Fiscal year ending Mar 2025: revenue $84M, net income $-4M$84MFY25Fiscal year ending Mar 2026: revenue $149M, net income $45M$149MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026$149M+77.1%$49M$45M30.1%
Mar 2025$84M+48.4%$20M$-4M-5.1%
Mar 2024$57M+65.8%$11M$20M35.5%
Mar 2023$34M+5.9%$4M$4M10.4%
Mar 2022$32M+27.1%$5M$9M27.6%
Mar 2021$25M+41.1%$2M$5M20.1%
Mar 2020$18M+137.6%$-2M$-2M-12.5%
Mar 2019$8M—$-9M$-9M-122.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$24M$1M$23M$0.03—
Mar 2025$7M$2M$6M$0.00—
Mar 2024$-3M$1M$-4M$0.02—
Mar 2023$3M$6M$-2M$0.00—
Mar 2022$7M$1M$6M$0.01—
Mar 2021$3M——$0.00—
Mar 2020$-2M——$0.00—
Mar 2019$-7M——$-0.01—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$145M
Net income, trailing 12 months
$60M
RevenueNet income
Three months to Dec 2024: revenue $14M, net income $-11M$14MDec ’24Three months to Mar 2025 (from the annual report): revenue $32M, net income $17M$32MMar ’25Three months to Jun 2025: revenue $40M, net income $-6M$40MJun ’25Three months to Sep 2025: revenue $36M, net income $14M$36MSep ’25Three months to Dec 2025: revenue $32M, net income $19M$32MDec ’25Three months to Mar 2026 (from the annual report): revenue $41M, net income $18M$41MMar ’26Three months to Jun 2026: revenue $32M, net income $6M$32MJun ’26Three months to Sep 2026: revenue $40M, net income $17M$40MSep ’26

Latest quarter to Sep 2026: revenue $40M (+10.4% on a year earlier), net income $17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Elite Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$149 M
Operating income
$49 M
Net income
$45 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$138 M
Total liabilities
$39 M
Total equity
$99 M

As of March-2026

Insider trading at Elite Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$35 K
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$35 K
open market only
Insiders on file
21
since
$26 K-$562 K$0Oct 2024: bought $0 (0 trades), sold $562 K (2 trades)Oct 24Jul 2025: bought $10 K (1 trades), sold $116 K (1 trades)JulAug 2025: bought $0 (0 trades), sold $260 K (1 trades)AugOct 2025: bought $0 (0 trades), sold $496 K (1 trades)OctAug 2026: bought $9 K (1 trades), sold $0 (0 trades)AugOct 2026: bought $26 K (1 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Elite Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Barry H. DashDirectorBuy+100,000$0.260$26 K3.37 MForm 4
filed Barry H. DashDirectorBuy+30,000$0.290$9 K3.27 MForm 4
filed Douglas PlasscheEVP OperationsOption exercise+2.50 M$0.030$75 K6.00 MForm 4
filed Douglas PlasscheEVP OperationsSell-800,000$0.620$496 K3.50 MForm 4
filed Elite Pharmaceuticals Inc /NV/EVP OperationsOption exercise+2.50 M$0.030$75 K4.30 MForm 4
filed Elite Pharmaceuticals Inc /NV/EVP OperationsSell-500,000$0.520$260 K1.80 MForm 4
filed Kirko KirkovChief Commercial OfficerBuy+16,366$0.590$10 K16,366Form 4
filed Douglas PlasscheEVP OperationsSell-200,000$0.580$116 K2.30 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Elite Pharmaceuticals, Inc. scorecard#

Passes 12 of the 15 checks that could be worked out: strongest in growth (6 of 6), weakest in financial health (2 of 3). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth6 of 6
    • ✓Revenue grew in the newest year77.1%Revenue up 77.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years63.3%63.3% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median63.3%63.3% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✓Earnings per share grew in the newest year0.03 vs 0.00Diluted EPS 0.03 in fiscal 2025 against 0.00 the year before (report's currency).
    • ✓Net income higher than five years earlier$45 M$45 M in fiscal 2025 against $5 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$45 MNet income $45 M in fiscal 2025.
    • ✗Profitable in each of the last five years4 of 5Profitable in 4 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median33.0%33.0% against Pharmaceutical's median of 1.8% (74 companies).
    • ✓Return on equity above 15%58.9%58.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier33.0%33.0% in fiscal 2025 against 10.8% in 2022.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities6.5×Current ratio 6.45 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✓Operating income covers interest five times446.4×Operating income 446.4 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year6.6%Diluted shares up 6.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Elite Pharmaceuticals, Inc.'s statements, beside the median of Pharmaceutical.

Elite Pharmaceuticals, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin33.0%1.8%
Net margin30.1%-1.5%
Return on equity58.9%-0.9%
Revenue growth, 3 years a year63.3%2.5%
Revenue growth77.1%7.3%
Free cash flow margin15.3%6.0%

6of 8on the Piotroski tests of financial strength

  • The share count rose 6.6% in the year.
  • Receivables grew 104% while revenue grew 77%: customers are paying later, or sales were booked ahead of cash.
  • Revenue has grown 8 years in a row.

Elite Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Elite Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017
Income statement
Revenue1498457343225187.67.59.6
Cost of revenue744430181714104.73.55.9
Gross profit7540261715128.02.93.93.7
Research and development5.78.06.96.24.15.15.57.69.68.3
General and administrative189.07.15.14.53.33.33.12.32.1
Operating expenses262016139.79.810121311
Operating income4920113.75.12.1−2.3−9.2−9.1−7.4
Interest and finance income0.20.00.00.00.00.00.00.00.00.0
Interest expense and finance costs0.10.10.61.10.20.30.40.40.30.2
Other non-operating income (expense)7.7−20−100.31.22.00.0−0.84.39.3
Income before tax57−0.10.54.06.34.1−2.2−10.0−4.71.9
Income tax124.3−200.4−1.7——−0.7−1.0−1.9
Income from discontinued operations——————1.1———
Net income including minority interests——————−2.2−9.3——
Net income attributable to shareholders45−4.3203.68.95.1−2.2−9.3−3.73.8
Earnings per share, basic0.040.000.020.000.010.010.00-0.010.000.03
Earnings per share, diluted0.030.000.020.000.010.00r0.00-0.01-0.01-0.01
Shares, weighted average (basic)1,0731,0681,0151,0131,011943832814796839
Shares, weighted average (diluted)1,1381,0681,0231,0131,011943993816798845
Balance sheet
Cash and cash equivalents30117.17.88.53.21.12.37.211
Receivables6029193.13.13.54.11.30.70.9
Inventory2116139.66.75.04.14.54.96.4
Other current assets1.31.00.51.00.50.50.90.70.90.5
Current assets1125840221912108.91418
Property, plant and equipment101010106.06.67.28.49.09.0
Right-of-use (leased) assets1.52.02.40.01.00.20.4———
Other intangible assets4.85.66.36.36.66.66.66.67.76.4
Total assets138968441352625243134
Accounts payable6.13.02.72.41.40.91.61.41.71.0
Current liabilities1712137.86.75.88.66.95.13.3
Lease liabilities (non-current)1.01.62.0—0.80.00.2———
Non-current liabilities2231134.13.24.25.76.17.35.3
Total liabilities394326129.9101413128.6
Retained earnings−76−121−116−136−140−149−154−152−143−139
Shareholders' equity99545829251611−2.54.626
Total equity—————1611−2.5——
Total liabilities and equity138968441352625243134
Shares outstanding1,0771,0681,0681,0141,011r1,009840r825803928
Cash-flow statement
Depreciation and amortization1.11.21.31.31.21.31.31.31.00.7
Share-based compensation0.20.20.20.00.00.00.10.10.20.4
Cash from operating activities247.5−3.2r3.36.53.2−1.8−6.8−4.8−7.9
Capital expenditure−0.9−1.6−0.8−5.7−0.5—————
Intangible assets bought—−0.9——————−0.1−0.0
Cash from investing activities−0.9−2.4−0.8−5.7−0.5−0.3−0.00.3−0.3r−1.1
Debt repaid————————−0.1−0.2
Shares issued—————0.01.42.1r2.07.6
Cash from financing activities−4.3−0.83.3r1.7−0.7−0.90.71.61.78.1
Change in cash194.2−0.7−0.75.3—−1.1−4.9−3.4r−0.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Elite Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Manufacturing$148 M99%
  • Manufacturing Fees$148 M99%
  • Scheduled Products Manufacturing Fees$141 M95%
  • Indirect Sales to Wholesalers$83 M55%
  • Direct Sales to Wholesalers$65 M44%
  • Unscheduled Products Manufacturing Fees$6 M4.3%
  • Licensing$1 M0.7%
  • Unscheduled Products Licensing Fees$1 M0.4%
  • Scheduled Products Licensing Fees$0 M0.3%

Source: SEC annual report (XBRL data) · as of Mar 31, 2026

Events at Elite Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Results announced 9

Elite Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Elite Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2009$1 MA long-registered or listed companyUnder $2 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Elite Pharmaceuticals, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $155 K a year.

Certified, FY2025
1
#1,982 among companies on value.today
Worker positions
1
Median wage offered
$155 K
a year, full-time
Applications filed
1
Elite Pharmaceuticals, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Manager Product Development (Pharmaceutical)Natural Sciences Managers1$155 K

Where: Northvale, NJ 1

Elite Pharmaceuticals, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$155 K1
FY202311$120 K1
FY202222$138 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Elite Pharmaceuticals, Inc.

How Elite Pharmaceuticals, Inc. compares in Pharmaceutical

  • Revenue$149 M · higher than 25% of 324
  • Net margin41.6% · higher than 98% of 313
  • Revenue growth77.1% · higher than 93% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Elite Pharmaceuticals, Inc.🇺🇸$42 M—41.6%+77.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Employees:
As of June 25, 2026
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Elite Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Elite Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Elite Pharmaceuticals, Inc.? Suggest a correction